Hubbry Logo
ThioredoxinThioredoxinMain
Open search
Thioredoxin
Community hub
Thioredoxin
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Thioredoxin
Thioredoxin
Thioredoxin
View on Wikipedia
from Wikipedia
TXN
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesTXN, TRDX, TRX, TRX1, thioredoxin, Trx80
External IDsOMIM: 187700; MGI: 98874; HomoloGene: 128202; GeneCards: TXN; OMA:TXN - orthologs
Orthologs
SpeciesHumanMouse
Entrez

7295

22166

Ensembl

ENSG00000136810

ENSMUSG00000028367

UniProt

P10599

P10639

RefSeq (mRNA)

NM_003329
NM_001244938

NM_011660

RefSeq (protein)

NP_001231867
NP_003320

NP_035790

Location (UCSC)Chr 9: 110.24 – 110.26 MbChr 4: 57.94 – 57.96 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Thioredoxin (TRX or TXN) is a class of small redox proteins known to be present in all organisms. It plays a role in many important biological processes, including redox signaling. In humans, thioredoxins are encoded by TXN and TXN2 genes.[5][6] Loss-of-function mutation of either of the two human thioredoxin genes is lethal at the four-cell stage of the developing embryo. Although not entirely understood, thioredoxin is linked to medicine through their response to reactive oxygen species (ROS). In plants, thioredoxins regulate a spectrum of critical functions, ranging from photosynthesis to growth, flowering and the development and germination of seeds. Thioredoxins play a role in cell-to-cell communication.[7]

Occurrence

[edit]

They are found in nearly all known organisms and are essential for life in mammals.[8][9]

Function

[edit]

The primary function of thioredoxin (Trx) is the reduction of oxidized cysteine residues and the cleavage of disulfide bonds.[10] Multiple in vitro substrates for thioredoxin have been identified, including ribonuclease, choriogonadotropins, coagulation factors, glucocorticoid receptor, and insulin. Reduction of insulin is classically used as an activity test.[11] The thioredoxins are maintained in their reduced state by the flavoenzyme thioredoxin reductase, in a NADPH-dependent reaction.[12] Thioredoxins act as electron donors to peroxidases and ribonucleotide reductase.[13] The related glutaredoxins share many of the functions of thioredoxins, but are reduced by glutathione rather than a specific reductase.

Structure and mechanism

[edit]

Thioredoxin is a 12-kD oxidoreductase protein. Thioredoxin proteins also have a characteristic tertiary structure termed the thioredoxin fold. The active site contains a dithiols in a CXXC motif. These two cysteines are the key to the ability of thioredoxin to reduce other proteins.

For Trx1, this process begins by attack of Cys32, one of the residues conserved in the thioredoxin CXXC motif, onto the oxidized group of the substrate.[14] Almost immediately after this event Cys35, the other conserved Cys residue in Trx1, forms a disulfide bond with Cys32, thereby transferring 2 electrons to the substrate which is now in its reduced form. Oxidized Trx1 is then reduced by thioredoxin reductase, which in turn is reduced by NADPH as described above.[14]

Mechanism of Trx1 reducing a substrate

Trx1 can regulate non-redox post-translational modifications.[15] In the mice with cardiac-specific overexpression of Trx1, the proteomics study found that SET and MYND domain-containing protein 1 (SMYD1), a lysine methyltransferase highly expressed in cardiac and other muscle tissues, is also upregulated. This suggests that Trx1 may also play a role in protein methylation via regulating SMYD1 expression, which is independent of its oxidoreductase activity.[15]

Plants have an unusually complex complement of Trx's composed of six well-defined types (Trxs f, m, x, y, h, and o) that reside in diverse cell compartments and function in an array of processes. Thioredoxin proteins move from cell to cell, representing a novel form of cellular communication in plants.[7] Protein folding studies on Thioredoxin revealed that a minimum peptide length of 83 residues is required to acquire secondary and tertiary structure as shown by Ghosal et.al in 1999.

Interactions

[edit]

Thioredoxin has been shown to interact with:

Effect on cardiac hypertrophy

[edit]

Trx1 has been shown to downregulate cardiac hypertrophy, the thickening of the walls of the lower heart chambers, by interactions with several different targets. Trx1 upregulates the transcriptional activity of nuclear respiratory factors 1 and 2 (NRF1 and NRF2) and stimulates the expression of peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α).[26][27] Furthermore, Trx1 reduces two cysteine residues in histone deacetylase 4 (HDAC4), which allows HDAC4 to be imported from the cytosol, where the oxidized form resides,[28] into the nucleus.[29] Once in the nucleus, reduced HDAC4 downregulates the activity of transcription factors such as NFAT that mediate cardiac hypertrophy.[14] Trx 1 also controls microRNA levels in the heart and has been found to inhibit cardiac hypertrophy by upregulating miR-98/let-7.[30] Trx1 can regulate the expression level of SMYD1, thus may indirectly modulate protein methylation for purpose of cardiac protection.[15]

Thioredoxin in skin care

[edit]

Thioredoxin is used in skin care products as an antioxidant in conjunction with glutaredoxin and glutathione.[citation needed]

Thioredoxin-Like Proteins

[edit]

NrdH from Mycobacterium tuberculosis is a distinctive thioredoxin-like protein, functionally similar to thioredoxins but with a sequence more akin to glutaredoxins. Unlike typical glutaredoxins, NrdH can accept electrons from thioredoxin reductase (TrxR) to drive ribonucleotide reduction, a critical step in DNA synthesis. Structural analysis reveals a thioredoxin fold with conserved redox motifs—CVQC and WSGFRP—that form a hydrogen-bond network and hydrophobic patch, stabilizing TrxR binding.[31] This unique blend of glutaredoxin sequence features with thioredoxin activity underscores NrdH's adaptive role in M. tuberculosis' redox regulation.

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Thioredoxin

View on Grokipedia
from Grokipedia
Thioredoxin (Trx) is a small, ubiquitous protein present in all organisms, consisting of approximately 105-110 and featuring a conserved Cys-Gly-Pro-Cys that enables it to catalyze thiol-disulfide exchange reactions, thereby reducing oxidized proteins and maintaining cellular . First purified in 1964 from by Laurent et al. as a donor for , an enzyme critical for , Trx was identified through pioneering work by Peter Reichard and colleagues, marking the beginning of understanding its central role in . Structurally, Trx adopts a characteristic thioredoxin fold, comprising four β-strands flanked by three α-helices, with the active site disulfide bond formed between the two cysteine residues in the CXXC motif; in mammals, it exists primarily as two isoforms—cytosolic Trx1 (encoded by TXN) and mitochondrial Trx2 (encoded by TXN2)—both highly conserved across species. Functionally, Trx operates within the thioredoxin system, alongside NADPH-dependent thioredoxin reductase, to serve as a key antioxidant that scavenges reactive oxygen species (ROS), regulates protein folding, and modulates redox-sensitive signaling pathways. Beyond redox control, Trx influences diverse cellular processes, including transcription factor regulation (e.g., NF-κB and p53), apoptosis inhibition via interactions with ASK1, and cytokine-like activities that promote cell survival and proliferation. The biological significance of Trx extends to health and disease, where it protects against in conditions like cancer, , and neurodegenerative disorders, while its dysregulation can exacerbate and aging-related pathologies; for instance, elevated Trx levels in certain contexts act as a for oxidative damage, and Trx overexpression in model organisms extends lifespan by mitigating ROS-induced . Additionally, Trx interacts with regulatory proteins like thioredoxin-interacting protein (Txnip), which inhibits its activity to fine-tune signaling and metabolic . These multifaceted roles position Trx as a promising therapeutic target for redox-related diseases.

Discovery and Occurrence

Historical Discovery

Thioredoxin was first identified in 1964 as a low-molecular-weight protein serving as the hydrogen donor for in B, enabling the NADPH-dependent reduction of ribonucleotides to deoxyribonucleotides essential for . Researchers Tomas C. Laurent, Ellis C. Moore, and Peter Reichard purified the protein from bacterial extracts through a series of chromatographic steps, demonstrating its heat stability and ability to restore activity in assays lacking the native reductant. This discovery established thioredoxin as a key component of the bacterial thioredoxin system, alongside and NADPH. Subsequent biochemical studies in the late further characterized thioredoxin's structure and reactivity. In 1968, Arne Holmgren determined the complete of E. coli thioredoxin, revealing a 108-residue polypeptide with a conserved Cys-Gly-Pro-Cys (CXXC) motif at positions 32–35, which forms the redox-active dithiol/ center responsible for its thiol-reducing properties. The name "thioredoxin" was coined in the original 1964 isolation to denote its function as a protein facilitating thiol-disulfide reductions in , combining "thio" for sulfur-containing thiols and "redoxin" to indicate its role in reactions. By the 1980s, research expanded to eukaryotic systems, culminating in the of the human thioredoxin gene (TXN). In 1988, E. Wollman and colleagues isolated a full-length cDNA encoding human thioredoxin from an Epstein-Barr virus-transformed lymphoblastoid B-cell line, confirming its to the bacterial protein and expression as a 105-amino-acid polypeptide with the conserved CXXC . This cloning effort marked a pivotal milestone, enabling studies on thioredoxin's conservation across species and its broader cellular roles beyond bacterial .

Distribution Across Organisms

Thioredoxin is a ubiquitous protein present in nearly all organisms, spanning , , and eukaryotes, due to its evolutionary conservation across the three domains of life. This wide distribution underscores its fundamental role in maintaining cellular balance, with the protein encoded by conserved genes such as trxA in like Escherichia coli and TXN/TXN2 in humans. In prokaryotes, thioredoxin systems are essential for coping with , as demonstrated in E. coli where the trxA-encoded protein participates in numerous reactions and cellular processes. Bacterial thioredoxin systems are generally simpler, lacking the multiple isoforms and compartmentalization seen in eukaryotes. Eukaryotes, including , feature expanded thioredoxin families with multiple paralogs adapted to specific cellular compartments. In , isoforms such as Trx-f and Trx-m are localized to chloroplasts, where they contribute to the light-dependent regulation of photosynthetic enzymes through thiol-disulfide exchanges. In mammals, thioredoxin is critical for embryonic development, as evidenced by the embryonic lethality observed in knockout models of Trx1 or Trx2, highlighting its indispensable nature. In humans, thioredoxin expression is ubiquitous across tissues, with particularly elevated levels in the liver, , and immune cells, supporting organ-specific demands.

Structure and Mechanism

Molecular Structure

Thioredoxin is a small, monomeric protein with a of approximately 12 , comprising 105 in the cytosolic isoform Trx1. It exhibits a highly conserved thioredoxin fold, characterized by a central five-stranded antiparallel β-sheet surrounded by four α-helices, forming a β-α-β sandwich architecture that buries the hydrophobic core while exposing functional surfaces. This compact structure, with dimensions roughly 30 × 25 × 20 Å, enables thioredoxin's solubility and versatility in cellular environments across prokaryotes and eukaryotes. The of thioredoxin features a conserved CXXC motif, specifically Cys32-Gly-Pro-Cys35 in human Trx1, located at the of the second α-helix (α2). In the oxidized state, these cysteines form a bond that is central to the protein's capability, while in the , they exist as free thiols with a solvent-accessible geometry. Adjacent to this motif lies a shallow hydrophobic groove, formed by residues such as Pro74, Phe80, and Trp31, which accommodates substrates by providing non-covalent interactions that position bonds for nucleophilic attack by Cys32. The three-dimensional structure of thioredoxin was first elucidated by for the ortholog at 2.8 Å resolution in 1975, revealing the canonical fold with a resolution later refined to 1.68 Å. For human Trx1, high-resolution NMR solution structures of both oxidized (PDB: 1ERU) and reduced (PDB: 1ERT) forms, determined in 1994, confirm the conserved architecture: a twisted five-stranded β-sheet (β1-β5) packed against four α-helices (α1-α4), with minor conformational shifts upon state changes primarily at the . Post-translational modifications at residues modulate thioredoxin's structural stability and function. Oxidation beyond the can lead to higher-order aggregates, while S-nitrosylation at Cys69 and Cys73—non-catalytic residues—alters the solvent exposure of the and enhances under nitrosative stress. Glutathionylation at Cys73, often in response to oxidative conditions, protects against over-oxidation but may disrupt the hydrophobic groove, impacting substrate affinity.

Redox Mechanism

The of thioredoxin (Trx) involves a where the reduced form, Trx-(SH)₂, reduces target protein through a nucleophilic attack by the deprotonated N-terminal active-site (Cys32 in Trx1). This forms a transient mixed intermediate between Trx and the substrate, which is subsequently resolved by the second active-site (Cys35), releasing the reduced substrate and generating oxidized Trx-S₂. The cycle is highly efficient due to the low pK_a (approximately 7.0) of the N-terminal , which facilitates at physiological and enhances nucleophilicity. The oxidized Trx-S₂ is regenerated to Trx-(SH)₂ by (TrxR), a homodimeric flavenzyme that transfers electrons from NADPH to the Trx active-site . TrxR catalyzes this reduction via a ping-pong mechanism involving NADPH binding, FAD-mediated transfer, and resolution by the C-terminal motif (Cys497-SeCys498 in human TrxR1). The complete thioredoxin system thus comprises Trx, TrxR, and NADPH, enabling sustained reduction. The overall reaction for the system is: NADPH+H++Trx-S2+Protein-S-S→NADP++Trx-(SH)2+Protein-(SH)2\text{NADPH} + \text{H}^+ + \text{Trx-S}_2 + \text{Protein-S-S} \rightarrow \text{NADP}^+ + \text{Trx-(SH)}_2 + \text{Protein-(SH)}_2 Trx exhibits specificity for protein disulfides, particularly those involving cysteines with low pK_a values that allow efficient thiol-disulfide exchange, rather than low-molecular-weight disulfides like those in . For example, in the reduction of insulin disulfides—a classic substrate—the second-order rate constant for reduced Trx reacting with oxidized insulin is approximately 10^7 M^{-1} s^{-1}, reflecting the rapid kinetics of the nucleophilic attack. This preference ensures targeted regulation of protein function over indiscriminate reduction. The mechanism operates optimally at neutral (around 7.0–7.5), where the active-site cysteines maintain their favorable ionization states for . Activity is sensitive to , as excess oxidants can trap Trx in the oxidized form, impairing the cycle and contributing to cellular imbalance.

Core Functions

Antioxidant Activity

Thioredoxin (Trx) plays a central role in direct defense by serving as an to peroxiredoxins (Prxs), which efficiently reduce (H₂O₂) and alkyl hydroperoxides. This Trx-Prx interaction operates within the broader thioredoxin system, where reduced Trx regenerates oxidized Prxs, enabling sustained peroxide detoxification with second-order rate constants of 10⁶ to 10⁸ M⁻¹s⁻¹, far surpassing those of free cysteines. By neutralizing these (ROS), the system prevents downstream oxidative damage, including and protein carbonylation, which are hallmarks of unchecked cellular stress. For instance, loss of Trx-1 function in cardiac models elevates markers like and increases protein carbonyl levels, underscoring its protective role. In addition to peroxide scavenging, Trx supports under oxidative conditions by acting as the primary hydrogen donor for (RNR), the enzyme that converts ribonucleotides to deoxyribonucleotides for dNTP pool maintenance. This function is critical during cellular proliferation, as Trx system upregulation upon —such as in T cells—ensures adequate reducing equivalents for RNR despite ROS-induced metabolic perturbations, with glutathione-glutaredoxin providing only partial compensation. Impairment of this pathway, as seen in Trx reductase-deficient cells, leads to depleted dNTP levels and halted , highlighting Trx's indispensable role in redox-balanced nucleotide . Trx also confers cellular protection by inhibiting apoptosis through reduction of oxidized thiols in caspases, thereby suppressing their activation. Specifically, reduced Trx facilitates S-nitrosation of procaspase-3 and caspase-3, preventing proteolytic cascades in response to oxidative insults. Trx also inhibits apoptosis by directly binding to the N-terminal domain of apoptosis signal-regulating kinase 1 (ASK1), preventing its oligomerization and activation under reducing conditions, thereby blocking downstream JNK and p38 MAPK signaling. Furthermore, Trx levels are upregulated in response to ROS via the Nrf2 pathway, where Trx enhances Nrf2 DNA binding to activate antioxidant gene expression, amplifying the cell's defensive capacity. The essential nature of Trx's activity is evident from genetic studies: Trx1 in mice results in embryonic lethality at the stage (around 3.5 days post-fertilization), attributed to unchecked oxidative damage that impairs proliferation and . Heterozygous Trx1 mice remain viable but exhibit heightened sensitivity to , confirming Trx1's non-redundant role in early development.

Redox Signaling and Regulation

Thioredoxin functions as a key sensor and transducer in cellular redox signaling networks by modulating thiol-disulfide switches in target proteins, thereby influencing transcriptional responses to oxidative perturbations. Specifically, reduced thioredoxin reduces critical disulfide bonds in the transcription factor NF-κB, facilitating its DNA binding to promote pro-inflammatory and survival gene expression. These thiol-disulfide exchanges allow thioredoxin to fine-tune the balance between activation and repression of redox-sensitive transcription factors, enabling adaptive cellular responses without direct enzymatic catalysis beyond its dithiol motif. Beyond transcription, thioredoxin exhibits chaperone-like activity that aids in the refolding of oxidized cytosolic proteins, leveraging its thioredoxin fold to prevent aggregation. Members of the thioredoxin superfamily, including ER-resident proteins like (PDI), utilize this mechanism to resolve misfolded states induced by ER stress, ensuring control and mitigating unfolded protein response activation. This refolding assistance is particularly vital in the oxidizing ER environment, where thioredoxin's cycling helps restore functional conformations to substrates without compromising overall cellular . In regulating cell cycle progression and proliferation, thioredoxin controls PTEN oxidation status, thereby modulating the PI3K/Akt pathway; by reducing oxidized PTEN, thioredoxin maintains its activity, which dephosphorylates PIP3 to inhibit Akt signaling and prevent unchecked cell growth. Additionally, thioredoxin promotes the G1/S phase transition through stabilization of , enhancing its association with CDK4/6 to drive phosphorylation and entry into . These actions position thioredoxin as a pivotal regulator linking redox balance to proliferative control. Thioredoxin's involvement in stress responses further underscores its signaling role, as it is upregulated by electrophiles such as tert-butylhydroquinone through of the antioxidant response element (ARE) via Nrf2, enhancing cellular resilience to electrophilic insults. Similarly, under hypoxic conditions, thioredoxin expression increases independently of , facilitating adaptive adjustments in to support cell survival and metabolic reprogramming. This upregulation integrates environmental stressors into broader signaling cascades, allowing thioredoxin to orchestrate protective responses at the cellular level.

Isoforms and Variants

Cytosolic and Nuclear Trx1

Thioredoxin 1 (Trx1), the primary cytosolic and nuclear isoform of thioredoxin, is encoded by the TXN gene located on the long arm of human at position 9q31.3. This gene spans approximately 12.7 kb and consists of five exons, producing a mature protein of about 105 with a molecular weight of around 12 kDa. Trx1 expression is ubiquitous across tissues and is upregulated in response to , , and other cellular perturbations, reflecting its role as a key regulator. Notably, despite lacking a classical N-terminal , Trx1 can be secreted extracellularly via a non-classical pathway involving leaderless translocation across the plasma membrane, particularly under conditions of cellular stress such as hypoxia or oxidative damage. Trx1 is predominantly localized in the cytosol, where it maintains the redox balance of cellular proteins by serving as an electron donor in disulfide reduction reactions. However, upon activation by oxidative or nitrosative stress, Trx1 translocates to the nucleus, where it interacts with and reduces oxidized cysteine residues in transcription factors, thereby restoring their DNA-binding activity and modulating gene expression. Examples include the reduction of NF-κB and AP-1, which are critical for regulating genes involved in inflammation, proliferation, and apoptosis. The extracellular form of Trx1, released during stress, acts as a cytokine-like modulator, suppressing excessive inflammatory responses by inhibiting the production of pro-inflammatory mediators such as TNF-α and IL-6 in immune cells. Unique to Trx1, its extracellular variant exerts cytoprotective effects by inhibiting TNF-α-induced in endothelial and immune cells, primarily through suppression of activation and ROS-mediated signaling pathways. Additionally, Trx1 facilitates HIV-1 replication by reducing bonds in the viral nucleocapsid protein, enabling proper viral assembly and infectivity during the early stages of the viral life cycle. In pathological contexts, Trx1 overexpression is commonly observed in chronic inflammatory diseases, including and , where elevated serum levels correlate with disease severity and serve as a for oxidative stress-driven . Recent studies have further linked Trx1 to the metabolic regulation of regulatory B cells (Bregs), demonstrating that Trx1 maintains mitochondrial function and low ROS levels to promote IL-10-producing Breg differentiation, with reduced Trx1 expression contributing to dysregulated immunity in conditions like systemic .

Mitochondrial Trx2

Mitochondrial thioredoxin 2 (Trx2), encoded by the nuclear located on human chromosome 22q12.3, is a key component of the mitochondrial system. The TXN2 gene produces a precursor protein of 166 , featuring an N-terminal mitochondrial targeting sequence (MTS) of approximately 59 residues that directs the protein to the . Upon import, the MTS is cleaved by mitochondrial processing peptidase (MPP) and mitochondrial intermediate peptidase (MIP), yielding a mature Trx2 protein of about 107 that folds into a conserved thioredoxin fold with a -active CXXC motif. This enables Trx2 to function as a reductase, distinct from its cytosolic counterpart Trx1 in its exclusive localization. Trx2 is localized exclusively to the , where it maintains by reducing oxidized substrates in coordination with 2 (TrxR2) and NADPH. Its expression is tightly regulated and upregulated by the transcriptional coactivator PGC-1α, particularly under metabolic stress conditions such as oxidative challenge or energy demand, which promotes and defense. This induction enhances Trx2 levels to counteract (ROS) accumulation, ensuring integrity during physiological adaptations like exercise or pathological states including ischemia. In its specialized roles, Trx2 safeguards (mtDNA) from oxidative damage by scavenging ROS and repairing oxidized proteins, thereby preventing mutations that could impair function. It is essential for maintaining the state required for mitochondrial protein import, as disruptions in Trx2 activity lead to impaired translocation of nuclear-encoded precursors across the inner membrane. Additionally, Trx2 supports aconitase activity by reducing oxidative inactivation of this iron-sulfur cluster enzyme in the tricarboxylic acid cycle, preserving metabolic flux and energy production. Genetic ablation of Trx2 in mice results in embryonic lethality for global knockouts, while cardiac-specific knockout induces spontaneous characterized by ventricular dilation, , and due to unchecked ROS and signaling. Recent 2024 research underscores Trx2's critical involvement in neuronal resilience to , particularly in models of neurodevelopmental disorders like autism, where Trx2 dysregulation exacerbates synaptic deficits and ROS-mediated neuronal damage. In contexts, Trx2, supported by its reductase partner, mitigates stress and in neurons, highlighting its therapeutic potential for brain injury recovery.

Protein Interactions and Regulation

Key Interacting Partners

Thioredoxin (Trx) interacts directly with apoptosis signal-regulating kinase 1 (ASK1), a kinase, to inhibit its activation under conditions. Reduced Trx binds to the N-terminal thioredoxin-binding domain of ASK1, preventing homooligomerization and subsequent autophosphorylation that would otherwise activate downstream JNK and p38 MAPK pathways, thereby suppressing . This interaction is redox-dependent, with oxidation of Trx's catalytic cysteines leading to dissociation and ASK1 activation. Biophysical studies have determined the (Kd) for the reduced Trx1-ASK1 thioredoxin-binding domain complex to be approximately 0.3 μM, indicating high-affinity binding with 1:1 , while the oxidized form shows weaker affinity (Kd ≈ 6 μM). Recent cryo-electron structural of ASK1 in 2024 revealed that Trx1 acts as a negative allosteric effector by altering interdomain interactions in the asymmetric ASK1 dimer, stabilizing an inactive conformation. Trx also modulates transcription factors through redox regulation. It directly associates with redox factor-1 (Ref-1, also known as APEX1), enhancing Ref-1's ability to reduce critical cysteine residues in the AP-1 transcription factor complex (comprising Fos and Jun proteins), which promotes AP-1 DNA-binding activity and transcriptional activation in response to stimuli like phorbol esters. This Trx-Ref-1 interaction occurs in the nucleus and is potentiated by oxidative stress, such as ionizing radiation, facilitating AP-1-dependent gene expression involved in cell proliferation and survival. Additionally, Trx interacts with the tumor suppressor p53 to stabilize its DNA-binding conformation by reducing regulatory cysteines, augmenting p53's transcriptional activity on targets like p21 for cell cycle arrest and DNA repair under oxidative conditions. This redox regulation links Trx to p53-mediated responses without altering p53 protein levels or localization. In enzymatic partnerships, Trx serves as an for peroxiredoxins (Prx1 through Prx6), a family of peroxidases that detoxify and alkyl hydroperoxides. Reduced Trx regenerates oxidized Prxs by transferring electrons from its dithiol to the peroxidatic of Prx, enabling continuous reduction and protecting cells from oxidative damage, particularly in mitochondria and . Trx also reduces reductases (MsrA and MsrB), enzymes that repair oxidized residues in proteins by converting back to , thereby maintaining protein function and integrity during . This Trx-dependent repair mechanism is crucial for antioxidant defense, with Trx acting as the physiological reductant for Msrs in mammalian cells, outperforming alternatives like .

Inhibition by TXNIP

Thioredoxin-interacting protein (TXNIP), also known as vitamin D3 upregulated protein 1 (VDUP1), covalently binds to the redox-active CXXC motif of thioredoxin 1 (Trx1) through a bond formed by its own residue, thereby sequestering Trx1 and inhibiting its reducing activity, which leads to accumulation of (ROS). This interaction forms a stable mixed complex that prevents Trx1 from interacting with its target proteins, effectively blocking Trx1's functions. TXNIP expression is primarily induced by elevated glucose levels through the carbohydrate response element (ChoRE) in its promoter, mediated by the carbohydrate response element-binding protein (ChREBP), which drives TXNIP upregulation in metabolic stress conditions such as . Once expressed, TXNIP forms the inhibitory complex with Trx1, further suppressing Trx1's antioxidant activity and amplifying in glucose-responsive tissues like pancreatic beta cells. The TXNIP-Trx1 interaction enhances cellular by promoting ROS-mediated signaling pathways and exacerbates through activation of the , as TXNIP dissociation from Trx1 under triggers pro-inflammatory responses. Recent studies from 2023 to 2025 have linked TXNIP-Trx1 imbalance to the progression of , where elevated TXNIP impairs beta-cell survival, and to neurodegeneration, including models where TXNIP overexpression disrupts neuronal redox homeostasis and promotes amyloid-beta-induced toxicity. Therapeutic strategies targeting TXNIP inhibition, such as verapamil and its analogs, inhibit TXNIP expression to reduce its levels and thereby limit its binding to Trx1, restoring Trx1 activity, and alleviating in metabolic diseases like and improving beta-cell function and insulin sensitivity. These inhibitors have shown promise in preclinical models by reducing TXNIP expression and enhancing Trx1-mediated defense without broad off-target effects.

Physiological Roles

Cardiovascular System

Thioredoxin-1 (Trx1) overexpression in cardiomyocytes inhibits pathological cardiac induced by angiotensin II, primarily through upregulation of microRNA-98 (miR-98) and members of the let-7 family, which suppress cyclin D2 expression and . This mechanism involves Trx1-mediated reduction of , leading to decreased activation of hypertrophy-related signaling pathways such as MAPK/ERK. Additionally, Trx1 promotes nuclear translocation of 4 (HDAC4) by upregulating the chaperone DnaJB5, which facilitates HDAC4 deacetylation and recruitment to the nucleus, thereby repressing hypertrophic gene transcription. In models of pressure overload, such as transverse aortic constriction, Trx1 overexpression reduces , , and , preserving cardiac function. Conversely, inhibition of endogenous Trx1 exacerbates and in these models, highlighting its protective role against mechanical stress-induced maladaptive changes. In myocardial ischemia-reperfusion injury, Trx2, the mitochondrial isoform, limits infarct size by scavenging reactive oxygen species (ROS) generated during reperfusion, thereby preventing oxidative damage to mitochondrial membranes and proteins. Trx2 maintains mitochondrial integrity by reducing oxidized peroxiredoxins and inhibiting apoptosis signal-regulating kinase 1 (ASK1) activation, which suppresses downstream JNK and p38 MAPK pathways that promote cardiomyocyte death. Genetic overexpression of Trx2 in mouse models reduces ROS production, preserves ATP levels, and decreases cell death in the infarct zone, with infarct sizes reduced by up to 75% compared to controls. This protection extends to improved post-ischemic contractile function, underscoring Trx2's essential role in mitochondrial redox homeostasis during acute cardiac stress. Extracellular Trx1, secreted by endothelial and inflammatory cells, suppresses expression on endothelial cells in response to oxidized (ox-LDL), a key trigger in atherogenesis. By inhibiting activation via enhancement of Smad3 activity, Trx1 reduces to the , thereby attenuating the initiation of atherosclerotic plaque formation. In human umbilical vein endothelial cell models, recombinant Trx1 treatment significantly decreases mRNA and protein levels, correlating with diminished binding under flow conditions. Clinical studies reveal altered Trx levels in cardiovascular diseases, with elevated serum Trx1 observed in patients with , reflecting compensatory activation of the thioredoxin system amid chronic . However, in subsets of patients with and , decreased serum Trx levels correlate with disease severity and increased oxidative burden. Recent preclinical investigations, including 2024 studies on Trx2 overexpression and Trx1 mimetic peptides like CB3, demonstrate reduced infarct size and improved remodeling post-myocardial in murine models, paving the way for potential therapeutic exploration in human post-MI care.

Immune System Modulation

Thioredoxin (Trx) plays a critical role in modulating T cell function through both intracellular and extracellular mechanisms. Intracellular Trx1 supports T cell survival by maintaining redox homeostasis, while extracellular Trx1, secreted particularly by regulatory T cells (Tregs), preserves surface thiol groups on T cells, thereby inhibiting and promoting their persistence in inflammatory environments. This anti-apoptotic effect is essential for sustaining T cell populations during immune responses. Additionally, Trx1 influences T cell polarization; for instance, it helps regulate the Th1/Th2 balance by modulating production and receptor expression on T cells, indirectly favoring adaptive immune dynamics without directly driving proliferation or differentiation. In s, Trx acts as a metabolic rheostat that fine-tunes regulatory functions, particularly in interleukin-10 (IL-10)-producing regulatory s (Bregs). By controlling redox-sensitive , Trx limits excessive metabolic flux that would otherwise suppress IL-10 secretion, thereby enhancing Breg-mediated . This mechanism is disrupted in systemic (SLE), where B cell-specific Trx deficiency correlates with reduced Breg activity and heightened . Exogenous Trx supplementation restores IL-10 production across B cell subsets, highlighting its potential to recalibrate B cell for . Trx also shapes polarization toward an M2 phenotype, which dampens excessive . Trx1 promotes M2 differentiation by downregulating cell cycle inhibitors like p16^INK4A and reducing proinflammatory signals via AP-1 and Ref-1, thereby shifting macrophages away from the M1 state. This polarization favors tissue repair and resolution over destructive . Furthermore, Trx1 suppresses the in macrophages by sequestering thioredoxin-interacting protein (TXNIP), preventing its interaction with NLRP3 and subsequent IL-1β maturation, which curtails pyroptotic responses to . Links between Trx dysregulation and autoimmunity are evident in conditions like rheumatoid arthritis (RA), where Trx levels are markedly elevated in synovial fluid compared to osteoarthritis, reflecting heightened oxidative stress and synovial inflammation. This increase likely serves as a compensatory antioxidant response but may also perpetuate chronic activation of immune cells in the joint.

Role in Cancer

Thioredoxin plays a dual role in cancer, promoting tumor survival and progression in many contexts while also exhibiting tumor-suppressive effects through specific isoforms and mechanisms. Overexpression of the cytosolic isoform Trx1 and its reductase TrxR1 is frequently observed in aggressive cancers such as lung and breast carcinomas, where it enhances cell survival by scavenging reactive oxygen species (ROS) induced by chemotherapeutic agents, thereby conferring resistance to treatments like cisplatin and doxorubicin. This pro-survival function is particularly pronounced in hypoxic tumor microenvironments, where elevated Trx1 levels protect cancer cells from oxidative stress and apoptosis. In addition to survival advantages, thioredoxin facilitates by activating matrix metalloproteinases (MMPs), such as MMP-9, through regulation of the AP-1, which promotes degradation and cancer cell invasion. Recent bioinformatic analyses from , integrating single-cell sequencing and TCGA data, have linked high TXN (thioredoxin gene) expression to stem cells and poor prognosis, including shorter disease-free and in patients with high stemness signatures. Conversely, the mitochondrial isoform Trx2 exerts suppressive effects; its loss leads to excessive mitochondrial ROS accumulation, which drives DNA damage, genomic instability, and oncogene activation, thereby initiating tumorigenesis. Targeting the thioredoxin system with inhibitors like auranofin, which irreversibly binds TrxR, has been evaluated in a completed Phase I/II clinical trial for chronic lymphocytic leukemia (NCT01419691), showing potential ROS-inducing effects in overcoming resistance. As a , serum thioredoxin levels are elevated in patients and correlate with tumor burden and advanced disease stage, offering potential for non-invasive monitoring of progression and response to therapy.

Nervous and Endocrine Systems

Thioredoxin-1 provides by scavenging ROS and inhibiting in models of neurodegenerative diseases such as Alzheimer's and Parkinson's, where it modulates phosphorylation and aggregation. In the endocrine system, Trx interacts with Txnip to regulate glucose metabolism and insulin sensitivity, with dysregulation linked to progression. Recent 2025 studies indicate Trx2 supports mitochondrial function in , mitigating age-related through enhanced balance.

Clinical and Therapeutic Applications

Potential Therapies

The thioredoxin system has emerged as a promising target for cancer therapy through the development of thioredoxin reductase (TrxR) inhibitors, which disrupt redox homeostasis in tumor cells by inducing (ROS) overload and promoting . For instance, motexafin gadolinium, a redox-active TrxR inhibitor, has demonstrated selective toward cancer cells overexpressing the thioredoxin system, with preclinical and early clinical data showing enhanced radiosensitization in tumors. Although a phase III trial in 2003 for brain metastases from solid tumors did not meet its primary endpoint for survival improvement when combined with whole-brain radiation, phase I studies in multiforme confirmed its tolerability and potential to augment radiotherapy by inhibiting TrxR activity. More recent efforts focus on auranofin, an FDA-approved anti-rheumatic drug repurposed as a TrxR inhibitor, which has entered phase I/II trials (e.g., NCT01737502, completed in 2024 without published results as of November 2025) for advanced or recurrent non-small cell or small cell lung cancer, where it synergizes with to overcome resistance via ROS accumulation. In neurodegenerative diseases, strategies to activate or upregulate thioredoxin isoforms aim to mitigate oxidative stress and neuronal loss. Gene therapy approaches, such as lentiviral or transgenic overexpression of cytosolic Trx1 in Parkinson's disease (PD) models, have shown neuroprotective effects by preserving mitochondrial function and reducing dopaminergic neuron death in MPTP-treated mice and α-synuclein models. For example, Trx1 upregulation attenuates ROS-induced apoptosis and improves motor function in preclinical rodent models of PD, highlighting its potential for adeno-associated virus (AAV)-mediated delivery in future clinical translation. Similarly, for amyotrophic lateral sclerosis (ALS), preclinical data from 2023-2025 indicate that small molecule modulators targeting the thioredoxin-interacting protein (TXNIP) to enhance Trx activity, such as thioredoxin-mimetic peptides (TXM), protect motor neurons from oxidative damage in SOD1 mutant models, delaying disease progression without the toxicity seen in broad inhibitors like PX-12, which is primarily studied in oncology. For metabolic disorders like , disrupting TXNIP-Trx interactions restores thioredoxin antioxidant activity, improving insulin sensitivity and β-cell function. Verapamil, a , acts as a TXNIP disruptor by reducing its expression, thereby enhancing Trx-mediated ROS scavenging in pancreatic β-cells and preventing hyperglycemia-induced in preclinical diabetic models; observational studies have associated verapamil use with lower glucose levels in individuals with . Additionally, pioglitazone, a PPARγ agonist used in management, indirectly boosts Trx1 levels in cardiovascular tissues of models, reducing and via PPARγ-mediated transcriptional regulation, as evidenced by increased Trx1 protein in heart and following chronic treatment in fructose-fed rats. These approaches complement interventions by targeting Trx system impairment central to diabetic complications. Therapeutic targeting of the thioredoxin system faces challenges, including selectivity issues with natural inhibitors like , which irreversibly modifies TrxR's residue but also reacts with off-target thiols, limiting its clinical efficacy due to poor and non-specific ROS induction. Recent reviews from 2023-2025 emphasize therapies to overcome resistance, such as pairing TrxR inhibitors with chemotherapy agents like or CHK1 inhibitors, which amplify selectively in tumors while minimizing normal cell toxicity; for example, auranofin enhances efficacy in xenografts by dual inhibition of and thioredoxin pathways. Advances in structure-based design of non-covalent TrxR inhibitors promise improved and reduced side effects, paving the way for phase II/III trials in refractory cancers.

Applications in Skin Care

Thioredoxin (Trx), particularly the cytosolic isoform Trx1, has garnered interest in dermatological applications due to its potent capabilities when applied topically to the . In skincare formulations, sh-Polypeptide-2, a recombinant form of human Thioredoxin, provides unique antioxidant protection by reducing free radicals and maintains redox balance in the skin by modulating cellular redox states. sh-Polypeptide-2 is not classified as a hazardous substance under the Classification, Labelling and Packaging (CLP) regulation or the Globally Harmonized System (GHS). By scavenging (ROS) generated from (UV) radiation, topical Trx mitigates that contributes to . Specifically, extracellular Trx reverses UV-induced reductions in production, thereby preserving dermal matrix integrity and reducing the formation of wrinkles and sagging. This protective effect is enhanced when Trx is formulated alongside , as ascorbic acid boosts Trx levels and activity in cells, collectively preventing UV-mediated decreases in antioxidant enzymes and supporting overall resilience. In , topical Trx promotes migration and survival, facilitating re-epithelialization through modulation of redox signaling pathways. It also augments by inducing (VEGF) expression, which supports tissue repair in ischemic conditions. Animal models of full-thickness wounds, including those mimicking diabetic impairments, demonstrate accelerated closure rates with Trx application, attributed to reduced and enhanced synthesis. Recombinant human Trx1 has been incorporated into cosmetic formulations in since the early , often derived from microbial expression systems for stability in topical products like serums and creams. Japanese brands, such as FANCL's Core Effector serum, utilize Trx to target anti-aging benefits, with compositions designed to maintain protein integrity during storage and application. Recent reviews affirm Trx's efficacy in addressing through ROS neutralization and protection, though evidence remains primarily from preclinical and small-scale human studies, with limited large randomized controlled trials (RCTs) available. No major adverse effects have been reported from topical use, underscoring its safety profile in cosmetic contexts.

Thioredoxin-Like Proteins

Thioredoxin-like proteins constitute a diverse superfamily characterized by the presence of a conserved thioredoxin (Trx) fold, a β-α-β-α-ββ that forms the core domain for thiol- exchange reactions, but they exhibit functional adaptations distinct from canonical thioredoxins. In eukaryotic cells, prominent examples include the (PDI) family members, such as PDI itself and ERp57 (also known as PDIA3), which reside in the (ER) and facilitate through bond management. PDI comprises four thioredoxin-like domains (a, b, b', a'), with the catalytically active a and a' domains containing the CXXC motif essential for activity. In prokaryotes, bacterial analogs like DsbA and DsbC in the of perform similar roles; DsbA introduces bonds oxidatively, while DsbC isomerizes incorrect ones, both relying on the thioredoxin fold for substrate interaction. A key functional divergence among thioredoxin-like proteins lies in their roles, contrasting with the primarily reductive function of canonical thioredoxins in cytosolic or mitochondrial environments. PDI and ERp57 catalyze oxidative in the ER by forming and rearranging bonds in nascent polypeptides, leveraging the oxidizing ER milieu to ensure proper protein maturation, whereas thioredoxins typically reduce disulfides to maintain cellular reducing conditions. This specialization is enabled by low sequence identity—typically around 20% between thioredoxin and PDI active-site domains—yet preservation of the structural , including the catalytic CXXC motif and surrounding hydrophobic patches for substrate binding. ERp57, for instance, collaborates with and in the calreticulin/calnexin cycle to edit folding, highlighting its role in beyond simple oxidation. Evolutionarily, thioredoxin-like proteins likely emerged through ancient events within the thioredoxin superfamily, allowing diversification of functions across cellular compartments. In eukaryotes, the PDI family expanded via duplications to yield at least 20 members in humans, each tailored to specific ER substrates or stress responses. In , thioredoxin-h (Trx-h) types exemplify hybrid functions, combining cytosolic reduction with nucleus-targeted regulation of transcription factors and detoxification, reflecting adaptations to photosynthetic and environmental stresses through segmental duplications in genomes like .

Comparison to Glutaredoxins

Thioredoxins and glutaredoxins share notable structural similarities as small thiol-disulfide oxidoreductases, both typically ranging from 9 to 16 kDa in size and featuring a conserved within a characteristic thioredoxin fold—a β-α-β-α-β with a central β-sheet surrounded by α-helices. This fold enables their roles in regulation, but glutaredoxins exhibit greater sequence and structural diversity, including monothiol (CGFS) and dithiol (CPYC) variants, compared to the more uniform WCGPC motif in thioredoxins. A key mechanistic distinction lies in their electron donors: thioredoxins rely on NADPH and for reduction, whereas glutaredoxins are reduced by (GSH) via the system, allowing glutaredoxins to integrate with the broader glutathione-dependent network. Functionally, glutaredoxins and thioredoxins diverge in substrate preferences and catalytic mechanisms. Glutaredoxins, particularly dithiol forms like Grx1 and Grx2, specialize in deglutathionylation, efficiently reducing S-glutathionylated proteins and mixed disulfides with GSH, which helps maintain protein function under oxidative stress. In contrast, thioredoxins directly target intramolecular and intermolecular protein disulfides, facilitating thiol-disulfide exchange without requiring glutathione. Localization further differentiates them: Grx1 and Grx2 predominate in the cytosol and mitochondria, respectively, while Grx3 is primarily nuclear, enabling compartment-specific redox control, whereas thioredoxins show broader distribution across cellular compartments. Despite these differences, the two systems overlap in redox homeostasis, with thioredoxins handling high-flux (ROS) detoxification, such as H₂O₂ reduction via peroxiredoxins, and glutaredoxins contributing to iron-sulfur cluster biogenesis and repair, particularly through monothiol glutaredoxins like Grx3 and Grx4. Both exhibit dual roles in regulation, where they inhibit pro-apoptotic signaling by reducing oxidized and other targets, though thioredoxins more prominently suppress hydrogen peroxide-induced . Therapeutically, these distinctions offer targeted opportunities. Recent reviews emphasize the synergistic interplay of thioredoxin and glutaredoxin systems in cancer redox therapy, where dual inhibition—such as combining blockers with pathway disruptors—potentiates and overcomes tumor resistance in and other malignancies.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC3579385/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC10827563/
  3. https://pubmed.ncbi.nlm.nih.gov/14245400/
  4. https://pubmed.ncbi.nlm.nih.gov/14245401/
  5. https://pubmed.ncbi.nlm.nih.gov/3170595/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC10135697/
  7. https://www.ncbi.nlm.nih.gov/gene/948289
  8. https://www.ncbi.nlm.nih.gov/gene/7295
  9. https://www.pnas.org/doi/10.1073/pnas.0308701101
  10. https://www.uniprot.org/uniprotkb/P0AA25/entry
  11. https://www.sciencedirect.com/science/article/abs/pii/S0891584918326388
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC535839/
  13. https://www.liebertpub.com/doi/10.1089/ars.2011.4327
  14. https://www.mdpi.com/2076-3921/12/5/1078
  15. https://www.uniprot.org/uniprotkb/P10599/entry
  16. https://www.sciencedirect.com/science/article/pii/S096921260100154X
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC2745927/
  18. https://www.pnas.org/doi/10.1073/pnas.1110736108
  19. https://febs.onlinelibrary.wiley.com/doi/full/10.1046/j.1432-1327.2000.01701.x
  20. https://www.sciencedirect.com/science/article/pii/S0021925819835627
  21. https://www.sciencedirect.com/science/article/pii/S0014579300017385
  22. https://www.pnas.org/doi/10.1073/pnas.100114897
  23. https://www.jbc.org/article/S0021-9258(19)84734-8/pdf
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC4749877/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC10968256/
  26. https://www.nature.com/articles/s41467-018-04274-w
  27. https://www.pnas.org/doi/10.1073/pnas.0704898104
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC10215468/
  29. https://elifesciences.org/articles/53627
  30. https://www.liebertpub.com/doi/10.1089/ars.2014.5849
  31. https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-018-0803-3
  32. https://www.researchgate.net/publication/26685622_Thioredoxin_Regulates_Cell_Cycle_via_the_ERK12-Cyclin_D1_Pathway
  33. https://pubmed.ncbi.nlm.nih.gov/12660821/
  34. https://www.mdpi.com/2076-3921/12/4/944
  35. https://www.genecards.org/cgi-bin/carddisp.pl?gene=TXN
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC9746700/
  37. https://pubmed.ncbi.nlm.nih.gov/11118054/
  38. https://aacrjournals.org/cancerres/article/60/23/6688/506916/Thioredoxin-Nuclear-Translocation-and-Interaction
  39. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2013.00269/full
  40. https://www.mdpi.com/2076-3921/13/9/1078
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC12454041/
  42. https://www.nature.com/articles/s41590-024-01798-w
  43. https://www.ncbi.nlm.nih.gov/gene/25828
  44. https://www.uniprot.org/uniprotkb/Q99757/entry
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC6727865/
  46. https://www.ahajournals.org/doi/10.1161/circulationaha.114.012725
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC2959178/
  48. https://academic.oup.com/cardiovascres/article/66/3/562/333716
  49. https://www.sciencedirect.com/science/article/pii/S2213231725001910
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC3463972/
  51. https://www.aging-us.com/article/104071/text
  52. https://link.springer.com/article/10.1007/s12031-024-02270-y
  53. https://pubmed.ncbi.nlm.nih.gov/38513765/
  54. https://pubmed.ncbi.nlm.nih.gov/9564042/
  55. https://pubmed.ncbi.nlm.nih.gov/25037217/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC4148872/
  57. https://elifesciences.org/articles/95199
  58. https://pubmed.ncbi.nlm.nih.gov/10585464/
  59. https://www.sciencedirect.com/science/article/pii/S0021925819533154
  60. https://pubmed.ncbi.nlm.nih.gov/11807942/
  61. https://www.sciencedirect.com/science/article/pii/S0006291X08007870
  62. https://pubmed.ncbi.nlm.nih.gov/16766796/
  63. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2013.00514/full
  64. https://www.jbc.org/article/S0021-9258%2820%2952315-6/fulltext
  65. https://pubmed.ncbi.nlm.nih.gov/15705778/
  66. https://www.sciencedirect.com/science/article/pii/S0021925818665081
  67. https://academic.oup.com/endo/article/146/5/2397/2500353
  68. https://www.nature.com/articles/s12276-023-01019-8
  69. https://www.sciencedirect.com/science/article/abs/pii/S0141813025074355
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC12589959/
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC9387585/
  72. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2018.00640/full
  73. https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.110.239426
  74. https://doi.org/10.1016/j.cell.2008.05.038
  75. https://www.jci.org/articles/view/17700
  76. https://rem.bioscientifica.com/view/journals/rem/2024/1/REM-23-0029.xml
  77. https://www.ahajournals.org/doi/abs/10.1161/circulationaha.114.012725
  78. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0076226
  79. https://pubmed.ncbi.nlm.nih.gov/11407728/
  80. https://www.sciencedirect.com/science/article/abs/pii/S002191501000420X
  81. https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.202300792RR
  82. https://ashpublications.org/blood/article/117/3/857/125578/Increased-thioredoxin-1-production-in-human
  83. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.883116/full
  84. https://www.ahajournals.org/doi/10.1161/atvbaha.112.249334
  85. https://pubmed.ncbi.nlm.nih.gov/11841836/
  86. https://pubmed.ncbi.nlm.nih.gov/11410516/
  87. https://doi.org/10.1016/j.bbcan.2013.02.005
  88. https://doi.org/10.3389/fmolb.2022.883297
  89. https://pubmed.ncbi.nlm.nih.gov/21963718/
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC11851766/
  91. https://clinicaltrials.gov/study/NCT01419691
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC3529324/
  93. https://clinicaltrials.gov/study/NCT00032097
  94. https://www.mdpi.com/1422-0067/26/5/2084
  95. https://www.nature.com/articles/s41420-024-01848-0
  96. https://www.sciencedirect.com/science/article/pii/S2213231725004124
  97. https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04314-5
  98. https://pubmed.ncbi.nlm.nih.gov/30932940/
  99. https://pmc.ncbi.nlm.nih.gov/articles/PMC2831122/
  100. https://www.sciencedirect.com/science/article/pii/S0021925820656836
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC11428833/
  102. https://www.nature.com/articles/s41467-024-48076-9
  103. https://www.sigmaaldrich.cn/CN/en/sds/sigma/t0910
  104. https://www.sciencedirect.com/science/article/pii/S2949688825000012
  105. https://pubmed.ncbi.nlm.nih.gov/38685741/
  106. https://www.mdpi.com/2076-3921/11/10/1993
  107. https://www.researchgate.net/publication/327104291_Thioredoxin-1_augments_wound_healing_and_promote_angiogenesis_in_a_murine_ischemic_full-thickness_wound_model
  108. https://pmc.ncbi.nlm.nih.gov/articles/PMC12166283/
  109. https://www.ulprospector.com/en/eu/PersonalCare/Detail/13339/2387017/RedoxySense
  110. https://www.specialchem.com/cosmetics/guide/new-beauty-innovations-japanese-market
  111. https://patents.google.com/patent/US20150250700A1/en
  112. https://journals.sagepub.com/doi/10.1089/ars.2014.5849
  113. https://www.sciencedirect.com/science/article/pii/S0021925819753745
  114. https://www.cell.com/cell/pdf/S0092-8674%2805%2901412-1.pdf
  115. https://onlinelibrary.wiley.com/doi/full/10.1002/pro.3530
  116. https://febs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1742-4658.2010.07793.x
  117. https://www.jbc.org/article/S0021-9258%2819%2975374-5/pdf
  118. https://www.sciencedirect.com/science/article/pii/S0006291X12010418
  119. https://pmc.ncbi.nlm.nih.gov/articles/PMC9529593/
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC6928294/
  121. https://pmc.ncbi.nlm.nih.gov/articles/PMC6327914/
  122. https://www.mdpi.com/2076-3921/13/10/1201
Add your contribution
Related Hubs
User Avatar
No comments yet.